Suppr超能文献

亚洲抗抑郁药物剂量相关因素:亚洲精神药物处方研究的结果

Factors Associated With Antidepressant Dosing in Asia: Findings From the Research on Asian Psychotropic Prescription Study.

作者信息

Rajaratnam Kamini, Xiang Yu-Tao, Tripathi Adarsh, Chiu Helen Fung Kum, Si Tian-Mei, Chee Kok-Yoon, Avasthi Ajit, Grover Sandeep, Chong Mian-Yoon, Kuga Hironori, Kanba Shigenobu, He Yan-Ling, Lee Min-Soo, Yang Shu-Yu, Udomratn Pichet, Kallivayalil Roy Abraham, Tanra Andi J, Maramis Margarita, Shen Winston Wu-Dien, Sartorius Norman, Kua Ee-Heok, Tan Chay-Hoon, Mahendran Rathi, Shinfuku Naotaka, Sum Min Yi, Baldessarini Ross J, Sim Kang

机构信息

From the *Department of General Psychiatry, Institute of Mental Health, Singapore; †Unit of Psychiatry, Faculty of Health Sciences, University of Macau, Macao SAR, China; ‡Department of Psychiatry, King George's Medical University, Chowk, Lucknow, India; §Department of Psychiatry, Chinese University of Hong Kong, Hong Kong, China; ‖National Clinical Research Center for Mental Disorders & the Key Laboratory of Mental Health, Ministry of Health (Peking University). Peking University Institute of Mental Health (the Sixth Hospital), Beijing, China; ¶Department of Psychiatry & Mental Health, Tunku Abdul Rahman Institute of Neurosciences, Kuala Lumpur Hospital, Kuala Lumpur, Malaysia; #Department of Psychiatry, Post Graduate Institute of Medical Education and Research (PGIMER), Chandigarh, India; **Department of Psychiatry, Kaohsiung Chang Gung Memorial Hospital-Kaohsiung Medical Center and School of Medicine, Chang Gung University, Taiwan; ††Department of Neuropsychiatry, Kyushu University, Fukuoka, Japan; ‡‡Department of Psychiatric Epidemiology, Shanghai Mental Health Center, Shanghai, China; §§Department of Psychiatry, College of Medicine, Korea University, Seoul, Korea; ‖‖Department of Pharmacy, Taipei City Hospital, Taipei, Taiwan; ¶¶Department of Psychiatry, Faculty of Medicine, Prince of Songkla University, Songkhla, Thailand; ##Department of Psychiatry, Pushpagiri Medical College, Thiruvalla, India; ***Department of Psychiatry, Hasanuddin University Faculty of Medicine, Makassar, Sulawesi Selatan, Indonesia; †††Dr. Soetomo Hospital, Faculty of Medicine, Airlangga University, Jawa Timur, Indonesia; ‡‡‡Departments of Psychiatry, TMU-Wan Fang Medical Center and School of Medicine, Taipei Medical University, Taiwan; §§§Association for the Improvement of Mental Health Programmes, Geneva, Switzerland; ‖‖‖Department of Psychological Medicine, National University of Singapore; ¶¶¶Department of Pharmacology, National University of Singapore, Singapore; ###International Center for Medical Research, Kobe University School of Medicine, Kobe, Japan; ****Research Division, Institute of Mental Health, Singapore; ††††International Consortium for Mood & Psychotic Disorder Research, McLean Hospital, Belmont, Massachusetts and Department of Psychiatry, Harvard Medical School, Boston, MA; ‡‡‡‡Department of General Psychiatry, Institute of Mental Health, Singapore.

出版信息

J Clin Psychopharmacol. 2016 Dec;36(6):716-719. doi: 10.1097/JCP.0000000000000591.

Abstract

In this study, we sought to examine factors associated with dosing of antidepressants (ADs) in Asia. Based on reported data and clinical experience, we hypothesized that doses of ADs would be associated with demographic and clinical factors and would increase over time. This cross-sectional, pharmacoepidemiological study analyzed data collected within the Research Study on Asian Psychotropic Prescription Pattern for Antidepressants from 4164 participants in 10 Asian countries, using univariate and multivariate methods. The AD doses varied by twofold among countries (highest in PR China and RO Korea, lowest in Singapore and Indonesia), and averaged 124 (120-129) mg/d imipramine-equivalents. Average daily doses increased by 12% between 2004 and 2013. Doses were significantly higher among hospitalized patients and ranked by diagnosis: major depression > anxiety disorders > bipolar disorder, but were not associated with private/public or psychiatric/general-medical settings, nor with age, sex, or cotreatment with a mood stabilizer. In multivariate modeling, AD-dose remained significantly associated with major depressive disorder and being hospitalized. Doses of ADs have increased somewhat in Asia and were higher when used for major depression or anxiety disorders than for bipolar depression and for hospitalized psychiatric patients.

摘要

在本研究中,我们试图考察亚洲地区与抗抑郁药(ADs)给药相关的因素。基于已报道的数据和临床经验,我们推测抗抑郁药的剂量会与人口统计学和临床因素相关,且会随时间增加。这项横断面药物流行病学研究采用单变量和多变量方法,分析了来自亚洲10个国家4164名参与者的抗抑郁药亚洲精神药物处方模式研究中的数据。各国的抗抑郁药剂量相差两倍(中国和韩国最高,新加坡和印度尼西亚最低),平均为124(120 - 129)毫克/天的丙咪嗪等效剂量。2004年至2013年间,日均剂量增加了12%。住院患者的剂量显著更高,且按诊断排序为:重度抑郁症>焦虑症>双相情感障碍,但与私立/公立或精神科/普通内科环境无关,也与年龄、性别或与心境稳定剂的联合治疗无关。在多变量建模中,抗抑郁药剂量仍与重度抑郁症和住院显著相关。亚洲地区抗抑郁药的剂量有所增加,用于重度抑郁症或焦虑症时的剂量高于双相抑郁症以及住院精神科患者。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验